	US 12,263,158 B2
	Tizanidine liquid preparation and use thereof
Gang Chen, Sichuan (CN); Gongzheng Chen, Sichuan (CN); Song Lin, Sichuan (CN); Rashmi Rohit Prasade, Sichuan (CN); and Ganesh Dattatray Chavan Patil, Sichuan (CN)
Assigned to FIDELITY BIOPHARMA CO., New Haven, CT (US)
Appl. No. 17/918,130
Filed by FIDELITY BIOPHARMA CO., New Haven, CT (US)
PCT Filed May 7, 2022, PCT No. PCT/CN2022/091371 § 371(c)(1), (2) Date Oct. 11, 2022, PCT Pub. No. WO2022/247609, PCT Pub. Date Dec. 1, 2022.
Claims priority of application No. 202110577512.4 (CN), filed on May 26, 2021.
Prior Publication US 2023/0414580 A1, Dec. 28, 2023
Int. Cl. A61K 31/433 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01)

CPC A61K 31/433 (2013.01) [A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01)]

22 Claims

1. A liquid oral pharmaceutical composition, comprising

a) about 0.2-10 mg/mL of tizanidine hydrochloride;

b) a chelating agent;

c) water, and

a pharmaceutically acceptable excipient,

wherein pH of the liquid pharmaceutical composition is between 3.5 and 6.5.